… care for advanced non–small cell lung cancer (NSCLC) … 7.7 mo) was observed in
T790M-negative patients compared … of erlotinib for patients with stable disease on prior gefitinib …

… the gefitinib (P=0.008), erlotinib, icotinib, and only OS in gefitinib … the OS times of patients
compared to placebo. However, the … treatments had no impact on the efficacy of anlotinib in …

… compare bevacizumab–erlotinib versus erlotinib alone in the … Efficacy endpoints (eg, overall
survival and time from enrolment … Osimertinib was administered in the second line, third line, …

… as first-line therapies in targeted therapy research include erlotinib (8) and gefitinib (9); …
, the present study indicated that, compared with the control group, the third-line treatment of …

… , we designed this randomized, phase-2 study comparing the efficacy and tolerability of
erlotinib 100 mg/d vs. gefitinib 250 mg/d in patients with EGFR-mutated advanced NSCLC. …

… ) compared with placebo as a third-line or subsequent therapy in patients with non-small cell
lung cancer (… The most frequently used EGFR TKIs were gefitinib, erlotinib, and icotinib. For …

… as third-line treatment agent in non-oncogene driven … In the univariate analysis, there was
a significant difference in the … ), such as gefitinib, afatinib, and erlotinib, are recommended …

… efficacy and acceptable toxicity of apatinib plus gefitinib as a … trial comparing oral VEGFR2
TKI, apatinib, plus gefitinib versus … therapy for locally advanced and metastatic non-small cell …

… We aimed to evaluate the efficacy of anlotinib in patients with … common targeted agents were
gefitinib, erlotinib, and icotinib. … -Lung 8 trial compared the efficacy of afatinib and erlotinib in …

… erlotinib as EGFR mutations targeted therapies has been considered for third-line therapy,
the efficacy for the … PFS compared to placebo plus BSC as third-line treatment in patients with …